- Home
- Publications
- Publication Search
- Publication Details
Title
Advances and challenges in therapeutic targeting of NRF2
Authors
Keywords
-
Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-01-09
DOI
10.1016/j.tips.2022.12.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response
- (2022) Dylan G. Ryan et al. iScience
- Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode
- (2022) Nikolaos Georgakopoulos et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2
- (2022) Boushra Bathish et al. FREE RADICAL BIOLOGY AND MEDICINE
- Cruciferous Vegetable Intake and Bulky DNA Damage within Non-Smokers and Former Smokers in the Gen-Air Study (EPIC Cohort)
- (2022) Marco Peluso et al. Nutrients
- Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study
- (2022) Giovanni Pellacani et al. Journal of Clinical Medicine
- Electrophile versus oxidant modification of cysteine residues: Kinetics as a key driver of protein modification
- (2022) Max B. Sauerland et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance
- (2022) Rohini Srivastava et al. FREE RADICAL BIOLOGY AND MEDICINE
- Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism
- (2021) Yuta Horie et al. Communications Biology
- Cruciferous vegetable consumption and pancreatic cancer: A case-control study
- (2021) Maia E.W. Morrison et al. Cancer Epidemiology
- Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder
- (2021) Andrew W. Zimmerman et al. Molecular Autism
- Nrf2 activation does not affect adenoma development in a mouse model of colorectal cancer
- (2021) Elena V. Knatko et al. Communications Biology
- 4-Octyl-Itaconate and Dimethyl Fumarate Inhibit COX2 Expression and Prostaglandin Production in Macrophages
- (2021) Ciana Diskin et al. JOURNAL OF IMMUNOLOGY
- Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera
- (2021) Jesse R. Poganik et al. Nature Communications
- Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
- (2021) Hongyu Ding et al. Science Advances
- The isoquinoline PRL-295 increases the thermostability of Keap1 and disrupts its interaction with Nrf2
- (2021) Sharadha Dayalan Naidu et al. iScience
- Beyond repression of Nrf2: An update on Keap1
- (2020) Aleksandra Kopacz et al. FREE RADICAL BIOLOGY AND MEDICINE
- An open-source drug discovery platform enables ultra-large virtual screens
- (2020) Christoph Gorgulla et al. NATURE
- A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
- (2020) Jonathan M. Ghergurovich et al. Nature Chemical Biology
- Biomarker Exploration in Human Peripheral Blood Mononuclear Cells for Monitoring Sulforaphane Treatment Responses in Autism Spectrum Disorder
- (2020) Hua Liu et al. Scientific Reports
- Current Landscape of NRF2 Biomarkers in Clinical Trials
- (2020) Yoko Yagishita et al. Antioxidants
- Safety and Efficacy of Omaveloxolone in Friedreich's Ataxia ( MOXIe Study)
- (2020) David R. Lynch et al. ANNALS OF NEUROLOGY
- A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design
- (2020) Jonathan W. Riess et al. Clinical Lung Cancer
- Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
- (2020) James H. Lewis et al. CTS-Clinical and Translational Science
- Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis
- (2020) Yun Pyo Kang et al. Cell Metabolism
- Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
- (2020) Keito Okazaki et al. Nature Communications
- Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
- (2019) Antonio Cuadrado et al. NATURE REVIEWS DRUG DISCOVERY
- Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex
- (2019) Balyn W. Zaro et al. JOURNAL OF IMMUNOLOGY
- A Comparative Assessment Study of Known Small-Molecule Keap1−Nrf2 Protein–Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity
- (2019) Kim T. Tran et al. JOURNAL OF MEDICINAL CHEMISTRY
- Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability
- (2019) Phillip R. Lazzara et al. JOURNAL OF MEDICINAL CHEMISTRY
- Broccoli or Sulforaphane: Is It the Source or Dose That Matters?
- (2019) Yoko Yagishita et al. MOLECULES
- AMPK leads to phosphorylation of the transcription factor Nrf2, tuning transactivation of selected target genes
- (2019) Manuel Matzinger et al. Redox Biology
- NRF2 and the Hallmarks of Cancer
- (2018) Montserrat Rojo de la Vega et al. CANCER CELL
- Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice
- (2018) Anna-Kaisa Ruotsalainen et al. CARDIOVASCULAR RESEARCH
- Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment
- (2018) Sarah A. Best et al. Cell Metabolism
- The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
- (2018) Masayuki Yamamoto et al. PHYSIOLOGICAL REVIEWS
- C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape
- (2018) Sharadha Dayalan Naidu et al. Scientific Reports
- The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
- (2018) Anna Hammer et al. Annals of Clinical and Translational Neurology
- Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors
- (2018) Benjamin G. Richardson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
- (2018) David R. Lynch et al. Annals of Clinical and Translational Neurology
- The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer
- (2017) Shasha Tao et al. MOLECULAR CARCINOGENESIS
- Liver injury associated with dimethyl fumarate in multiple sclerosis patients
- (2017) Monica A Muñoz et al. Multiple Sclerosis Journal
- KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients
- (2017) Luisa Quinti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes
- (2017) Annika S. Axelsson et al. Science Translational Medicine
- Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer
- (2017) Volkan I Sayin et al. eLife
- Liver injury associated with dimethyl fumarate in multiple sclerosis patients
- (2017) Monica A Muñoz et al. Multiple Sclerosis Journal
- Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery
- (2016) Thomas G. Davies et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
- (2016) Ulf Schulze-Topphoff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming
- (2016) Tetsuya Saito et al. Nature Communications
- Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
- (2016) Ralf A. Linker et al. Therapeutic Advances in Chronic Disease
- Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans
- (2015) E. V. Knatko et al. Cancer Prevention Research
- Molecular basis of the Keap1–Nrf2 system
- (2015) Takafumi Suzuki et al. FREE RADICAL BIOLOGY AND MEDICINE
- Rapid and Sustainable Detoxication of Airborne Pollutants by Broccoli Sprout Beverage: Results of a Randomized Clinical Trial in China
- (2014) P. A. Egner et al. Cancer Prevention Research
- The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
- (2014) John D. Hayes et al. TRENDS IN BIOCHEMICAL SCIENCES
- Proteomic Analysis of Ubiquitin Ligase KEAP1 Reveals Associated Proteins That Inhibit NRF2 Ubiquitination
- (2013) B. E. Hast et al. CANCER RESEARCH
- The absence of macrophage Nrf2 promotes early atherogenesis
- (2013) Anna-Kaisa Ruotsalainen et al. CARDIOVASCULAR RESEARCH
- Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
- (2013) Yoshinobu Ichimura et al. MOLECULAR CELL
- Disruption of Nrf2, a Key Inducer of Antioxidant Defenses, Attenuates ApoE-Mediated Atherosclerosis in Mice
- (2008) Thomas E. Sussan et al. PLoS One
- Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles
- (2008) H. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started